Skip to main content

Advertisement

SpringerLink
Log in

Fresh from the biotech pipeline: record-breaking FDA approvals

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

New drug approvals reached an all-time high in 2023, with five gene therapies, the first CRISPR–Cas9-edited therapy and a disease-modifying Alzheimer’s drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: FDA new drug approvals (CDER and CBER).
Fig. 2: FDA approvals by therapy area.

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. Fresh from the biotech pipeline: record-breaking FDA approvals. Nat Biotechnol 42, 355–361 (2024). https://doi.org/10.1038/s41587-024-02166-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-024-02166-7

  • Springer Nature America, Inc.

Search

Navigation